title: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
abstract: BACKGROUND
  This multicenter, open-label, prospective, single cohort study evaluated the effectiveness and safety of adalimumab in a clinical setting reflecting the Canadian standard of care for the treatment of patients with rheumatoid arthritis (RA).
  
  
  METHODS
  Patients ≥ 18 years of age with a history of active RA ≥ 3 months and fulfilling Canadian requirements for biological therapy received adalimumab 40 mg subcutaneously every other week for 12 weeks. Pre-study DMARD treatment regimens, corticosteroids, or NSAIDs were allowed throughout the study. The primary effectiveness outcome measure was the mean change in 28-joint disease activity score (DAS28) from baseline to Week 12. Secondary measures included the proportion of patients achieving joint remission (DAS28 < 2.6) and low-disease activity (DAS28 < 3.2) at Week 12, and European League Against Rheumatism (EULAR: moderate and good) and American College of Rheumatology (ACR: ACR20, 50, and 70) responses, as well as responses in ACR core components at Weeks 4, 8, and 12. Subgroup analysis included a comparison of patients naïve to biological DMARD (BDMARD) therapy versus BDMARD-experienced patients. Safety was assessed in terms of adverse and serious adverse events.
  
  
  RESULTS
  A total of 879 patients (mean disease duration > 12 years) were enrolled; 772 (87.9%) completed the 12-week period. Adalimumab treatment was associated with rapid and sustained improvements in the signs and symptoms of RA. Significant improvements in mean DAS28 score were observed as early as Week 4. After 12 weeks of adalimumab treatment, 15.3% and 28.9% of patients achieved clinical remission and low-disease activity, respectively. Similarly, significant improvements in ACR core components were observed as early as Week 4, with continued improvements occurring through 12 weeks. Patients naïve to BDMARD therapy demonstrated numerically greater clinical responses when compared with patients who had experienced prior BDMARD therapy, although both subgroups were associated with significant improvements from baseline. The rates and types of adverse events, as well as the results of laboratory measures, demonstrated that adalimumab was generally safe and well-tolerated.
  
  
  CONCLUSIONS
  This study demonstrated that, under conditions reflective of the normal clinical practice in Canada, adalimumab is an effective and safe treatment for patients with RA.
  
  
  BACKGROUND
  NCT00649545.
authors.affiliation: Department of Rheumatology, CHUM-Hôpital Notre Dame, Montreal, Quebec, Canada. bharaoui@videotron.ca.
authors.forename: Boulos
authors.initials: B
authors.lastname: Haraoui
authors.forename: Alfred
authors.initials: A
authors.lastname: Cividino
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Stewart
authors.forename: Benoît
authors.initials: B
authors.lastname: Guérette
authors.forename: Edward C
authors.initials: EC
authors.lastname: Keystone
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002170:Canada; D015331:Cohort Studies; D005260:Female; D006291:Health Policy / Q000639:trends*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011787:Quality of Health Care / Q000639:trends*; D011859:Radiography; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab
references.citation: Ann Rheum Dis. 2004 May;63(5):508-16
references.pmid: 15082480
references.citation: Rheumatology (Oxford). 2007 Jul;46(7):1191-9
references.pmid: 17504821
references.citation: Ann Rheum Dis. 2009 Dec;68(12):1863-9
references.pmid: 19147611
references.citation: J Rheumatol. 1982 Sep-Oct;9(5):789-93
references.pmid: 7175852
references.citation: Ann Rheum Dis. 1988 Sep;47(9):768-72
references.pmid: 3263088
references.citation: Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9
references.pmid: 16273792
references.citation: J Rheumatol. 1986 Oct;13(5):841-5
references.pmid: 3820193
references.citation: J Rheumatol. 2010 Nov;37(11):2237-46
references.pmid: 20889601
references.citation: Ann Rheum Dis. 2006 Jun;65(6):753-9
references.pmid: 16308341
references.citation: Arthritis Rheum. 2006 Jan;54(1):26-37
references.pmid: 16385520
references.citation: J Rheumatol. 2011 May;38(5):855-62
references.pmid: 21285171
references.citation: Arthritis Rheum. 2003 Jan;48(1):35-45
references.pmid: 12528101
references.citation: J Immunol. 1990 May 1;144(9):3347-53
references.pmid: 2109776
references.citation: Arthritis Rheum. 2004 May;50(5):1400-11
references.pmid: 15146409
references.citation: BMJ. 1996 May 11;312(7040):1215-8
references.pmid: 8634569
references.citation: Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1
references.pmid: 20674669
references.citation: Lancet. 1987 May 16;1(8542):1108-11
references.pmid: 2883443
references.citation: Ann Rheum Dis. 2001 Jul;60(7):660-9
references.pmid: 11406520
references.citation: Arthritis Rheum. 1988 Mar;31(3):315-24
references.pmid: 3358796
references.citation: N Engl J Med. 2001 Mar 22;344(12):907-16
references.pmid: 11259725
references.citation: Ann Rheum Dis. 2006 Jul;65(7):889-94
references.pmid: 16439435
references.citation: Arthritis Rheum. 1988 Aug;31(8):1041-5
references.pmid: 3136775
references.citation: J Rheumatol. 2003 Dec;30(12):2563-71
references.pmid: 14719195
references.citation: Arthritis Rheum. 1995 Jan;38(1):44-8
references.pmid: 7818570